Table 3 Drug related AEs, Occurring in more than 10% of patients.

From: Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer

AE

AP (n = 73)

AG (n = 84)

p value

Any grade

Grade 3

Grade 4

Any grade

Grade 3

Grade 4

Hematologic

Neutropenia

72 (98.6%)

16 (21.9%)

46 (63%)

63 (75.0%)

21 (25.0%)

17 (20.2%)

0.000

Febrile neutropenia

9 (12.3%)

9 (12.3%)

0

2 (2.4%)

1 (1.2%)

1 (1.2%)

0.0338

Anemia

68 (93.2%)

10 (13.7%)

3 (4.1%)

21 (25.0%)

4 (4.8%)

0

0.018

Thrombocytopenia

16 (21.9%)

1 (1.4%)

0

17 (20.2%)

6 (7.1%)

1 (1.2%)

0.069

Non-Hematologic

Neuropathy

53 (72.6%)

19 (26%)

0

42 (50.0%)

6 (7.1%)

0

0.001

Anorexia

24 (33.0%)

0

0

3 (3.6%)

0

0

0.000

Fatigue

25 (34.2%)

0

0

14 (16.7%)

0

0

0.011

Rash

27 (37%)

1 (1.4%)

0

28 (33.3%)

2 (2.4%)

0

0.238

Alopecia

73 (100.0%)

0

0

34 (40.5%)

0

0

0.000

Nausea

47 (64.4%)

2 (2.7%)

0

16 (19.1%)

0

0

0.000

Vomiting

45 (61.6%)

2 (2.7%)

0

14 (16.7%)

0

 

0.000

Diarrhea

9 (12.3%)

2 (2.7%)

0

2 (2.4%)

0

0

0.0339

Constipation

12 (16.4%)

0

0

0

0

0

0.000

Abdominal pain

10 (13.7%)

0

0

0

0

0

0.000

Skin hyperpigmentation

14 (19.2%)

0

0

8 (9.5%)

0

0

0.082

Blurred vision

4 (5.5%)

0

0

8 (9.5%)

0

0

0.516

Nail change

8 (11.0%)

0

0

19 (22.6%)

0

0

0.053

Edema

2 (2.7%)

0

0

20 (23.8%)

0

0

0.000

Myalgia

6 (8.2%)

0

0

20 (23.8%)

1 (1.2%)

0

0.009

  1. AP, nab-paclitaxel plus cisplatin; AG, nab-paclitaxel plus gemcitabine; AE, adverse event.